Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 2 · 50%High 0 · 0%

Irinotecan vs non‐irinotecan‐containing regimens

Overall survival · people with advanced gastric cancer

Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.87 [0.8, 0.95]
10 studies · 2135 participants
Moderate

Irinotecan vs non‐irinotecan‐containing regimens

Overall survival ‐ Other comparisons · people with advanced gastric cancer

It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.87 [0.76, 1]
2 studies · 809 participants
Very low

Irinotecan vs non‐irinotecan‐containing regimens

Overall survival ‐ Additive comparisons · people with advanced gastric cancer

Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.88 [0.76, 1.03]
3 studies · 500 participants
Low

Irinotecan vs non‐irinotecan‐containing regimens

Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer

Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.87 [0.75, 1]
6 studies · 826 participants
Moderate